{"id":"mangafodipir","rwe":[{"pmid":"39765773","year":"2024","title":"MnSOD Mimetics in Therapy: Exploring Their Role in Combating Oxidative Stress-Related Diseases.","finding":"","journal":"Antioxidants (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"38673932","year":"2024","title":"Manganese- and Platinum-Driven Oxidative and Nitrosative Stress in Oxaliplatin-Associated CIPN with Special Reference to Ca(4)Mn(DPDP)(5), MnDPDP and DPDP.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"37300475","year":"2023","title":"Four- to seven-year follow-up of pharmacological postconditioning with mangafodipir as an adjunct to primary PCI in ST-segment elevation myocardial infarction.","finding":"","journal":"Clinical physiology and functional imaging","studyType":"Clinical Study"},{"pmid":"35668508","year":"2022","title":"Trypanosoma cruzi iron superoxide dismutases: insights from phylogenetics to chemotherapeutic target assessment.","finding":"","journal":"Parasites & vectors","studyType":"Clinical Study"},{"pmid":"34943040","year":"2021","title":"The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOx.","finding":"","journal":"Antioxidants (Basel, Switzerland)","studyType":"Clinical Study"}],"tags":[{"label":"Paramagnetic Contrast Agent","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"V08CA05","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Magnetic resonance imaging of liver","category":"indication"},{"label":"Approved 1990s","category":"decade"},{"label":"Contrast Media","category":"pharmacology"},{"label":"Diagnostic Uses of Chemicals","category":"pharmacology"}],"phase":"marketed","safety":{"contraindications":["Autoimmune disease","Disease of liver","Disorder of immune function","Kidney disease","Nausea and vomiting","Peptic reflux disease"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MANGAFODIPIR","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:16:02.313490+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:16:07.621673+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MANGAFODIPIR","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:16:07.996548+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2096651/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:16:08.689504+00:00"}},"allNames":["mangafodipir","mangafodipir trisodium"],"offLabel":[],"synonyms":["mangafodipir","mangafodipir trisodium"],"timeline":[{"date":"1997-11-26","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"MANGAFODIPIR is a paramagnetic contrast agent, a small molecule modality developed for use in magnetic resonance imaging (MRI). It was originally developed and is currently owned by a pharmaceutical company. MANGAFODIPIR is approved by the FDA for the indication of liver imaging, with an approval date of 1997. The drug is off-patent, meaning it is no longer protected by patents, and there are no generic manufacturers. As an off-patent drug, its commercial status is uncertain.","approvals":[{"date":"1997-11-26","orphan":false,"company":"","regulator":"FDA"}],"ecosystem":[{"indication":"Magnetic resonance imaging of liver","otherDrugs":[{"name":"iron","slug":"iron","company":""}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","moaClass":"Magnetic Resonance Contrast Activity","modality":"Small Molecule","drugClass":"Paramagnetic Contrast Agent","explanation":"","oneSentence":"","technicalDetail":"MANGAFODIPIR is a gadolinium-based contrast agent that shortens the T1 relaxation time of surrounding tissues, resulting in enhanced contrast on T1-weighted MRI images."},"commercial":{"launchDate":"1997","_launchSource":"DrugCentral (FDA 1997-11-26, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4532","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MANGAFODIPIR","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MANGAFODIPIR","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:29:56.712707","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:16:10.251637+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"gadopentetate dimeglumine","drugSlug":"gadopentetate-dimeglumine","fdaApproval":"1988-06-02","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadodiamide","drugSlug":"gadodiamide","fdaApproval":"1993-01-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadoteridol","drugSlug":"gadoteridol","fdaApproval":"1992-11-16","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"gadoversetamide","drugSlug":"gadoversetamide","fdaApproval":"1999-12-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadobutrol","drugSlug":"gadobutrol","fdaApproval":"2011-03-14","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"gadofosveset","drugSlug":"gadofosveset","fdaApproval":"2008-12-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadopiclenol","drugSlug":"gadopiclenol","fdaApproval":"2022-09-21","patentExpiry":"Sep 19, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"mangafodipir","indications":{"approved":[{"name":"Magnetic resonance imaging of liver","source":"DrugCentral","snomedId":241622002,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"gadopentetate-dimeglumine","brandName":"gadopentetate dimeglumine","genericName":"gadopentetate dimeglumine","approvalYear":"1988","relationship":"same-class"},{"drugId":"gadodiamide","brandName":"gadodiamide","genericName":"gadodiamide","approvalYear":"1993","relationship":"same-class"},{"drugId":"gadoteridol","brandName":"gadoteridol","genericName":"gadoteridol","approvalYear":"1992","relationship":"same-class"},{"drugId":"gadoversetamide","brandName":"gadoversetamide","genericName":"gadoversetamide","approvalYear":"1999","relationship":"same-class"},{"drugId":"gadobutrol","brandName":"gadobutrol","genericName":"gadobutrol","approvalYear":"2011","relationship":"same-class"},{"drugId":"gadofosveset","brandName":"gadofosveset","genericName":"gadofosveset","approvalYear":"2008","relationship":"same-class"},{"drugId":"gadopiclenol","brandName":"gadopiclenol","genericName":"gadopiclenol","approvalYear":"2022","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02531880","phase":"PHASE1","title":"Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2024-11-19","conditions":["Epilepsy"],"enrollment":40,"completionDate":"2026-07-01"},{"nctId":"NCT06731738","phase":"PHASE2","title":"Mangafodipir - an Intracellular Contrast Agent for Magnetic Resonance Imaging (MRI): Measuring Manganese Uptake Rate in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) Patients.","status":"COMPLETED","sponsor":"IC TARGETS AS","startDate":"2024-11-22","conditions":["Heart Failure With Preserved Ejection Fraction (HFPEF)"],"enrollment":44,"completionDate":"2025-11-29"},{"nctId":"NCT06698614","phase":"","title":"MEMRI and Kidney Disease","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2024-11-07","conditions":["Acute Kidney Injury","Kidney Transplant","Vasculitis","Chronic Kidney Disease(CKD)"],"enrollment":120,"completionDate":"2029-11-07"},{"nctId":"NCT00727922","phase":"PHASE2","title":"Protective Effect of Mangafodipir Against Oxaliplatin Neurotoxicity","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-06","conditions":["Neurotoxic Disorders","Cancer"],"enrollment":23,"completionDate":"2011-04"},{"nctId":"NCT06652763","phase":"","title":"Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction","status":"RECRUITING","sponsor":"University of Leicester","startDate":"2024-10-10","conditions":["Heart Failure With Preserved Ejection Fraction","Type 2 Diabetes"],"enrollment":60,"completionDate":"2036-02"},{"nctId":"NCT03607669","phase":"","title":"Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2018-06-01","conditions":["Ischemic Cardiomyopathy","Dilated Cardiomyopathy","Hypertrophic Cardiomyopathy"],"enrollment":90,"completionDate":"2020-02-01"},{"nctId":"NCT03132129","phase":"","title":"Prevalence and Determinants of Subclinical Cardiovascular Dysfunction in Adults With Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"University of Leicester","startDate":"2017-10-24","conditions":["Diabetes Mellitus, Type 2","Diabetic Cardiomyopathies"],"enrollment":593,"completionDate":"2029-10-31"},{"nctId":"NCT01326715","phase":"PHASE1","title":"Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2013-10-17","conditions":["Multiple Sclerosis"],"enrollment":17,"completionDate":"2022-09-13"},{"nctId":"NCT01619423","phase":"PHASE1,PHASE2","title":"A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Egetis Therapeutics","startDate":"2012-09","conditions":["Advanced Metastatic (Stage IV) Colorectal Cancer"],"enrollment":186,"completionDate":"2016-12"},{"nctId":"NCT00966563","phase":"PHASE2","title":"Mangafodipir as an Adjunct to Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Egetis Therapeutics","startDate":"2009-12","conditions":["Myocardial Infarction"],"enrollment":20,"completionDate":"2013-07"},{"nctId":"NCT00671996","phase":"PHASE2","title":"Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Colon Cancer Stage Dukes' C","status":"COMPLETED","sponsor":"Egetis Therapeutics","startDate":"2008-06","conditions":["Chemotherapy","Colon Cancer"],"enrollment":14,"completionDate":"2010-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000022112","MMSL":"16743","NDDF":"007354","UNII":"N02W67RKJS","VUID":"4024107","VANDF":"4021090","INN_ID":"7330","RXNORM":"236987","UMLSCUI":"C0772321","chemblId":"CHEMBL2096651","ChEMBL_ID":"CHEMBL1201301","KEGG_DRUG":"D04848","DRUGBANK_ID":"DB06796","PUBCHEM_CID":"146019693","SNOMEDCT_US":"410872002","SECONDARY_CAS_RN":"140678-14-4","MESH_SUPPLEMENTAL_RECORD_UI":"C060076"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":181,"therapeuticAreas":["Gastroenterology"],"atcClassification":{"source":"DrugCentral","atcCode":"V08CA05","allCodes":["V08CA05"]},"biosimilarFilings":[],"recentPublications":[{"date":"2024 Nov 23","pmid":"39765773","title":"MnSOD Mimetics in Therapy: Exploring Their Role in Combating Oxidative Stress-Related Diseases.","journal":"Antioxidants (Basel, Switzerland)"},{"date":"2024 Apr 15","pmid":"38673932","title":"Manganese- and Platinum-Driven Oxidative and Nitrosative Stress in Oxaliplatin-Associated CIPN with Special Reference to Ca(4)Mn(DPDP)(5), MnDPDP and DPDP.","journal":"International journal of molecular sciences"},{"date":"2023 Nov","pmid":"37300475","title":"Four- to seven-year follow-up of pharmacological postconditioning with mangafodipir as an adjunct to primary PCI in ST-segment elevation myocardial infarction.","journal":"Clinical physiology and functional imaging"},{"date":"2022 Jun 6","pmid":"35668508","title":"Trypanosoma cruzi iron superoxide dismutases: insights from phylogenetics to chemotherapeutic target assessment.","journal":"Parasites & vectors"},{"date":"2021 Dec 3","pmid":"34943040","title":"The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOx.","journal":"Antioxidants (Basel, Switzerland)"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","brandName":"MANGAFODIPIR","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1997","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1997-11-26T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":null,"mah":null,"brand_name_local":"Teslascan","application_number":"EMEA/H/C/000137"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Teslascan","application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:16:10.251637+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}